Latest NEA Management Company, LLC Stock Portfolio
NEA Management Company, LLC Performance:
2025 Q3: 38.11%YTD: 52.64%2024: 4.7%
Performance for 2025 Q3 is 38.11%, and YTD is 52.64%, and 2024 is 4.7%.
About NEA Management Company, LLC and 13F Hedge Fund Stock Holdings
NEA Management Company, LLC is a hedge fund based in CHEVY CHASE, MD. On 30-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $25.9 Billions. In it's latest 13F Holdings report, NEA Management Company, LLC reported an equity portfolio of $1.8 Billions as of 30 Sep, 2025.
The top stock holdings of NEA Management Company, LLC are RYTM, ACLX, VRNA. The fund has invested 16.1% of it's portfolio in RHYTHM PHARMACEUTICALS INC and 13.7% of portfolio in ARCELLX INC.
The fund managers got completely rid off INOZYME PHARMA INC (INZY), ADAPTIMMUNE THERAPEUTICS PLC (ADAP) and IKENA ONCOLOGY INC (IKNA) stocks. They significantly reduced their stock positions in CRISPR THERAPEUTICS AG (CRSP), ARCELLX INC (ACLX) and CELCUITY INC (CELC). NEA Management Company, LLC opened new stock positions in IMAGENEBIO INC (IKNA). The fund showed a lot of confidence in some stocks as they added substantially to X4 PHARMACEUTICALS INC (XFOR).
The top stock holdings of NEA Management Company, LLC are RYTM, ACLX, VRNA. The fund has invested 16.1% of it's portfolio in RHYTHM PHARMACEUTICALS INC and 13.7% of portfolio in ARCELLX INC.
The fund managers got completely rid off INOZYME PHARMA INC (INZY), ADAPTIMMUNE THERAPEUTICS PLC (ADAP) and IKENA ONCOLOGY INC (IKNA) stocks. They significantly reduced their stock positions in CRISPR THERAPEUTICS AG (CRSP), ARCELLX INC (ACLX) and CELCUITY INC (CELC). NEA Management Company, LLC opened new stock positions in IMAGENEBIO INC (IKNA). The fund showed a lot of confidence in some stocks as they added substantially to X4 PHARMACEUTICALS INC (XFOR).
NEA Management Company, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that NEA Management Company, LLC made a return of 38.11% in the last quarter. In trailing 12 months, it's portfolio return was 61.13%.
New Buys
| Ticker | $ Bought |
|---|---|
| imagenebio inc | 407,541 |
New stocks bought by NEA Management Company, LLC
Additions
| Ticker | % Inc. |
|---|---|
| x4 pharmaceuticals inc | 347 |
Additions to existing portfolio by NEA Management Company, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| crispr therapeutics ag | -33.33 |
| arcellx inc | -18.69 |
| celcuity inc | -6.54 |
| verona pharma plc | -0.45 |
NEA Management Company, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| adaptimmune therapeutics plc | -4,094,020 |
| inozyme pharma inc | -9,750,760 |
| wheels up experience inc | -113,554 |
| ikena oncology inc | -804,084 |
NEA Management Company, LLC got rid off the above stocks
Sector Distribution
NEA Management Company, LLC has about 81.1% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 81.1 |
| Others | 10.6 |
| Consumer Defensive | 8.3 |
Market Cap. Distribution
NEA Management Company, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 46.8 |
| SMALL-CAP | 26.6 |
| MICRO-CAP | 15.3 |
| UNALLOCATED | 10.6 |
Stocks belong to which Index?
About 66.6% of the stocks held by NEA Management Company, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 66.6 |
| Others | 33.4 |
NEA Management Company, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of NEA Management Company, LLC
NEA Management Company, LLC has 29 stocks in it's portfolio. About 79.1% of the portfolio is in top 10 stocks. SNTI proved to be the most loss making stock for the portfolio. RYTM was the most profitable stock for NEA Management Company, LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 13.72 | 3,045,260 | 250,016,000 | reduced | -18.69 | ||
| ADAP | adaptimmune therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AUPH | aurinia pharmaceuticals inc | 2.41 | 3,969,830 | 43,866,700 | unchanged | 0.00 | ||
| BDTX | black diamond therapeutics i | 0.92 | 4,448,760 | 16,860,800 | unchanged | 0.00 | ||
| BHG | neuehealth inc | 1.00 | 2,726,920 | 18,188,500 | unchanged | 0.00 | ||
| CELC | celcuity inc | 5.81 | 2,144,260 | 105,926,000 | reduced | -6.54 | ||
| COUR | coursera inc | 8.27 | 12,867,800 | 150,682,000 | unchanged | 0.00 | ||
| CRSP | crispr therapeutics ag | 3.77 | 1,058,570 | 68,605,900 | reduced | -33.33 | ||
| CSBR | champions oncology inc | 0.61 | 1,713,720 | 11,096,300 | unchanged | 0.00 | ||
| CVRX | cvrx inc | 0.90 | 2,026,080 | 16,350,500 | unchanged | 0.00 | ||
| GLUE | monte rosa therapeutics inc | 3.13 | 7,692,300 | 56,999,900 | unchanged | 0.00 | ||
| GOSS | gossamer bio inc | 2.61 | 18,093,000 | 47,584,700 | unchanged | 0.00 | ||
| IKNA | imagenebio inc | 0.02 | 50,005 | 407,541 | new | |||
| IKNA | ikena oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| INZY | inozyme pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IVA | inventiva sa | 0.46 | 1,462,590 | 8,322,820 | unchanged | 0.00 | ||
| MRKR | marker therapeutics inc | 0.08 | 1,625,680 | 1,451,080 | unchanged | 0.00 | ||
| NKTX | nkarta inc | 0.41 | 3,568,780 | 7,387,380 | unchanged | 0.00 | ||
| ORIC | oric pharmaceuticals inc | 2.71 | 4,118,620 | 49,423,500 | unchanged | 0.00 | ||
| PHAT | phathom pharmaceuticals inc | 1.27 | 1,960,170 | 23,071,200 | unchanged | 0.00 | ||